Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.

Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, Lonzo M, Wiktor AE, Dogan A, Jenkins RB.

Am J Clin Pathol. 2013 Feb;139(2):144-50. doi: 10.1309/AJCP13GJAOJAYJMW.

PMID:
23355198
2.

[Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].

Xu Y, Yang W, Yang F, Lu Y, Cai X, Zhou X.

Zhonghua Bing Li Xue Za Zhi. 2014 Apr;43(4):226-30. Chinese.

PMID:
24915811
3.

Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.

Horii R, Matsuura M, Iwase T, Ito Y, Akiyama F.

Breast Cancer. 2014 Sep;21(5):598-604. doi: 10.1007/s12282-012-0436-0. Epub 2013 Jan 12.

PMID:
23307494
4.

Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.

Lim SJ, Cantillep A, Carpenter PM.

Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25.

PMID:
24075600
5.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
6.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

PMID:
24343743
7.

Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer:  A Cohort Study Emphasizing Equivocal Cases.

Shao T, Wood M, Wing A, Hnatovska M, Mendes M, Brendan Mullen J, Chang MC.

Am J Clin Pathol. 2016 Sep;146(3):339-45. doi: 10.1093/ajcp/aqw117.

PMID:
27543979
8.

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M.

BMC Cancer. 2010 Jul 28;10:396. doi: 10.1186/1471-2407-10-396.

9.

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.

Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M.

J Clin Pathol. 2011 Oct;64(10):880-3. doi: 10.1136/jclinpath-2011-200009. Epub 2011 Jul 14.

PMID:
21757431
10.

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.

Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.

PMID:
23121603
11.
12.

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

Arnould L, Roger P, Macgrogan G, Chenard MP, Balaton A, Beauclair S, Penault-Llorca F.

Mod Pathol. 2012 May;25(5):675-82. doi: 10.1038/modpathol.2011.201. Epub 2012 Jan 6.

13.

HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Uehara T, Fujimoto M, Tsuruyama T, Date H, Haga H.

Lung Cancer. 2014 Sep;85(3):373-8. doi: 10.1016/j.lungcan.2014.06.007. Epub 2014 Jul 7.

PMID:
25047676
14.

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).

Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY.

Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.

PMID:
20594272
15.

Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization.

Nakagawa T, Horii R, Ito Y, Iwase T, Akiyama F.

Breast Cancer. 2016 Jan;23(1):78-84. doi: 10.1007/s12282-014-0533-3. Epub 2014 Apr 26.

PMID:
24771412
16.

Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.

Stålhammar G, Farrajota P, Olsson A, Silva C, Hartman J, Elmberger G.

Ann Diagn Pathol. 2015 Aug;19(4):203-10. doi: 10.1016/j.anndiagpath.2015.04.002. Epub 2015 Apr 7.

PMID:
25921313
17.

HER2 status in breast cancer determined by IHC and FISH: comparison of the results.

Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.

Pol J Pathol. 2004;55(4):165-71.

PMID:
15757204
18.

Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.

Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V.

J Clin Pathol. 2012 Jun;65(6):503-6. doi: 10.1136/jclinpath-2011-200643. Epub 2012 Mar 3.

PMID:
22389512
19.

[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.

PMID:
17134563
20.

Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

Petroni S, Addati T, Mattioli E, Caponio MA, Quero C, Rubini V, Giotta F, Simone G.

Arch Pathol Lab Med. 2012 Sep;136(9):993-1000. doi: 10.5858/arpa.2011-0327-OA.

PMID:
22938586

Supplemental Content

Support Center